Skip to main content
OpenTrials
Completed

NCT Number: NCT04563767

Feasibility - Infinitome

The Infinitome Program from Omniscient has the ability to identify abnormal brain networks or connectomes using resting state functional MRI (rs-fMRI). This technology, which visualizes brain networks in three dimensions, was originally developed to ensure neurosurgeons avoid inadvertently lesioning cognitively eloquent brain regions during surgical operations. The potential of Infinitome in identifying connectome dysfunction for neurodegenerative diseases such as Alzheimer's disease has yet to be explored. This diagnostic technique may play a critical role for identifying disease brain networks that may benefit from targeted interventions in clinical trials.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alzheimer Disease Brain Diseases Central Nervous System Diseases Dementia Mental Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Tauopathies

Age range

40 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

HealthPartners Neuroscience Center

Saint Paul, Minnesota, 55130, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with a diagnosis of mild, moderate, or severe Alzheimer's disease
  • Age: 40 - 90 Years
  • Patients who are clinically indicated for an MRI

Exclusion criteria

  • fMRI contraindicated (eg. Implantable device, pacemaker, metallic implants, etc.)
  • Subject unable to tolerate sitting for a one hour fMRI
  • Other concerns as determined by the investigator

Treatment and study plan

Infinitome

Procedure

Added sequence of rs-fMRI.

Primary outcomes

  1. Number of Participants Who Completed Rs-fMRI

    Time frame: 4 months

    Percent of subjects who complete the sequence of the fMRI protocol. Range: 0-100. Higher percentage indicates more completion.

  2. Number of Subjects Whose Images Completed Analysis

    Time frame: 4 months

    Percent of subjects whose images were uploaded and analyzed by the Infinitome program. Range: 0-100. Higher percentage indicates more completion.

Sponsors and collaborators

Lead sponsor

HealthPartners Institute

Other

Registry information

Official study title

Feasibility of Utilizing the Infinitome Program to Evaluate Abnormal Large Scale Brain Networks in Alzheimer's Disease

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Sep 24, 2020
Registry last updated
Feb 17, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.